Source evidence Original filing metadata and source links for verification. 5 source fields
SEC form
4
Accepted by SEC
05 May 2025, 16:52:19 UTC
Prior SEC filing
09 Apr 2025
Next SEC filing
09 May 2025
Source filing
View source filing
Reporting owner 1 detail
Reporting owner signature
/s/ Madelyn Zeylikman, Attorney-in-Fact
Filing notes and source

Key filing fact

Michael R. Megna filed Form 4 for Kiniksa Pharmaceuticals International, plc (KNSA) on 05 May 2025.

Key facts

  • This page summarizes Michael R. Megna's Form 4 filing for Kiniksa Pharmaceuticals International, plc (KNSA).
  • 4 reported transactions and 4 derivative rows are listed below.
  • Accepted by SEC: 05 May 2025, 16:52.

Change

  • Previous filing in this sequence was filed on 09 Apr 2025.
  • Current net transaction value: $0.

Research use

  • This tells you what this filing adds before you inspect full transaction and derivative tables.
  • You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001464583 Primary reporting owner

Megna Michael R

Relationship
CHIEF ACCOUNTING OFFICER
Address
23 OLD BOND STREET, THIRD FLOOR, LONDON, UNITED KINGDOM
Signature
/s/ Madelyn Zeylikman, Attorney-in-Fact
Signature date
05 May 2025

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

KNSA transaction Derivative

Performance Share Unit

Award

Transaction value
$0
Shares
+3,270
Change %
Price
$0.000000
Shares after
3,270
Date
01 May 2025
Ownership
Direct
Underlying class
Class A Ordinary Share
Underlying amount
3,270
Exercise price
Footnotes
F1, F2, F3
KNSA transaction Derivative

Performance Share Unit

Award

Transaction value
$0
Shares
+3,433
Change %
Price
$0.000000
Shares after
3,433
Date
01 May 2025
Ownership
Direct
Underlying class
Class A Ordinary Share
Underlying amount
3,433
Exercise price
Footnotes
F1, F2, F4
KNSA transaction Derivative

Performance Share Option

Award

Transaction value
$0
Shares
+5,285
Change %
Price
$0.000000
Shares after
5,285
Date
01 May 2025
Ownership
Direct
Underlying class
Class A Ordinary Share
Underlying amount
5,285
Exercise price
$27.74
Footnotes
F2, F5
KNSA transaction Derivative

Performance Share Option

Award

Transaction value
$0
Shares
+5,456
Change %
Price
$0.000000
Shares after
5,456
Date
01 May 2025
Ownership
Direct
Underlying class
Class A Ordinary Share
Underlying amount
5,456
Exercise price
$27.74
Footnotes
F2, F6
* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 6 footnotes

Footnote F1

Each Performance Share Unit (PSU) represents a contingent right to receive one Class A Ordinary Share of the Issuer, based upon the achievement of certain pre-established performance criteria, as certified by the Issuer's Compensation Committee.

Footnote F2

The award is subject to an earnout percentage of 100%, 75%, 50% or 0%, depending on the date of performance criteria achievement. This figure represents achievement at the 100% earnout performance achievement.

Footnote F3

The PSUs shall vest, if at all, upon the submission to the U.S. Food and Drug Administration (the "FDA") of a biologics license application for KPL-387 for the treatment of recurrent pericarditis, subject to the Participant's continued employment with the Company, subject to certain exceptions.

Footnote F4

The PSUs shall vest, if at all, upon the approval by the FDA of the commercial sale and marketing in the United States of KPL-387 for the treatment of recurrent pericarditis, subject to the Participant's continued employment with the Company, subject to certain exceptions.

Footnote F5

The Performance Share Options shall vest and become exercisable, if at all, upon the submission to the FDA of a biologics license application for KPL-387 for the treatment of recurrent pericarditis, subject to the Participant's continued employment with the Company, with certain exceptions.

Footnote F6

The Performance Share Options shall vest and become exercisable, if at all, upon the approval by the FDA of the commercial sale and marketing in the United States of KPL-387 for the treatment of recurrent pericarditis, subject to the Participant's continued employment with the Company, subject to certain exceptions.

We use cookies and similar technologies to provide certain features, enhance the user experience and, if you allow them, measure engagement and deliver advertising. Analytics and marketing storage stay off until you grant consent. By clicking on "Agree and continue", you declare your consent to the use of the selected optional cookies. Manage preferences to update or revoke optional consent for future visits. For more information, see our Privacy Policy .